NCT03889912 2026-01-21
Intralesional Cemiplimab for Adult Patients With Cutaneous Squamous Cell Carcinoma or Basal Cell Carcinoma
Regeneron Pharmaceuticals
Phase 1 Completed
Clinical Trials
7 trialsNCT04826393 2025-10-22
ASP8374 + Cemiplimab in Recurrent Glioma
Dana-Farber Cancer Institute
Phase 1 Completed
NCT03192345 2024-08-07
A First-in-human Study of the Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of SAR439459 Monotherapy and Combination of SAR439459 and Cemiplimab in Patients With Advanced Solid Tumors
Sanofi
Phase 1 Completed
NCT03005782 2024-05-01
Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced Cancers
Regeneron Pharmaceuticals
Phase 1 Completed
NCT03002376 2020-04-20
An Exploratory Tumor Biopsy-driven Study to Understand the Relationship Between Biomarkers and Clinical Response in Melanoma Patients Receiving REGN2810 (Anti-PD-1)
Regeneron Pharmaceuticals
Phase 1 Completed
NCT03198130 2020-03-19
An Exploratory Tumor Biopsy-driven Study to Understand the Relationship Between Biomarkers and Clinical Response in Patients With Head and Neck Cancer Receiving REGN2810 (Anti-PD-1)
Regeneron Pharmaceuticals
Phase 1 Completed
NCT02383212 2020-01-27
Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies
Regeneron Pharmaceuticals
Phase 1 Completed